Skip to content
Tolmetin
Tolectin (tolmetin) is a small molecule pharmaceutical. Tolmetin was first approved as Tolectin on 1982-01-01. It is used to treat juvenile arthritis, osteoarthritis, and rheumatoid arthritis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tolmetin sodium
Tradename
Company
Number
Date
Products
TOLECTIN 600Johnson & JohnsonN-017628 DISCN1989-03-08
1 products, RLD
TOLECTINJohnson & JohnsonN-017628 DISCN1982-01-01
1 products, RLD
TOLECTIN DSJohnson & JohnsonN-018084 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
tolmetin sodiumANDA2023-03-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
juvenile arthritisEFO_0002609D001171M08
osteoarthritisEFO_0002506D010003M15-M19
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
— M01: Antiinflammatory and antirheumatic products
— M01A: Antiinflammatory and antirheumatic products, non-steroids
— M01AB: Acetic acid derivatives and related substances
— M01AB03: Tolmetin
— M02: Topical products for joint and muscular pain
— M02A: Topical products for joint and muscular pain
— M02AA: Antiinflammatory preparations, non-steroids for topical use
— M02AA21: Tolmetin
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—6———17
Drug interactionsD0043473————3
Food-drug interactionsD0185651————1
Chronic hepatitis cD019698EFO_0004220B18.21————1
Chronic painD059350HP_00125321————1
NeoplasmsD009369C801————1
LymphomaD008223C85.91————1
EndotoxemiaD0194461————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTOLMETIN
INNtolmetin
Description
Tolmetin is a monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug. It has a role as a non-steroidal anti-inflammatory drug and an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor. It is a member of pyrroles, a monocarboxylic acid and an aromatic ketone. It is a conjugate acid of a tolmetin(1-).
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
Identifiers
PDB—
CAS-ID26171-23-3
RxCUI10636
ChEMBL IDCHEMBL1020
ChEBI ID71941
PubChem CID5509
DrugBankDB00500
UNII IDD8K2JPN18B (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 710 documents
View more details
Safety
Black-box Warning
Black-box warning for: Tolmetin sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
57 adverse events reported
View more details